BACKGROUND: This study compared infusion set function for up to 1 week using either a Teflon(®) (Dupont(™), Wilmington, DE) catheter or a steel catheter for insulin pump therapy in type 1 diabetes mellitus. SUBJECTS AND METHODS: Twenty subjects participating in a randomized, open-labeled, crossover study were asked to wear two Quick-Set(®) and two Sure-T(®) infusion sets (both from Medtronic Minimed, Northridge, CA) until the infusion set failed or was worn for 1 week. All subjects wore a MiniMed continuous glucose monitoring system for the duration of the study. RESULTS: One subject withdrew from the study. There were 38 weeks of Sure-T wear and 39 weeks of Quick-Set wear with no difference in the survival curves of the infusion sets. There was, however, a 15% initial failure rate with the Teflon infusion set. After 7 days, both types of infusion sets had a 64% failure rate. Overall, 30% failed because of hyperglycemia and a failed correction dose, 13% were removed for pain, 10% were pulled out by accident, 10% had erythema and/or induration of>10 mm, 5% fell out because of loss of adhesion, and 4% were removed for infection. The main predictor of length of wear was the individual subject. There was no increase in hyperglycemia or daily insulin requirements when an infusion set was successfully used for 7 days (n=25 of 77 weeks). CONCLUSIONS: We found no difference between steel and Teflon infusion sets in their function over 7 days, although 15% of Teflon sets failed because of kinking on insertion. The strongest predictor of prolonged 7-day infusion set function was the individual subject, not the type of infusion set.
RCT Entities:
BACKGROUND: This study compared infusion set function for up to 1 week using either a Teflon(®) (Dupont(™), Wilmington, DE) catheter or a steel catheter for insulin pump therapy in type 1 diabetes mellitus. SUBJECTS AND METHODS: Twenty subjects participating in a randomized, open-labeled, crossover study were asked to wear two Quick-Set(®) and two Sure-T(®) infusion sets (both from Medtronic Minimed, Northridge, CA) until the infusion set failed or was worn for 1 week. All subjects wore a MiniMed continuous glucose monitoring system for the duration of the study. RESULTS: One subject withdrew from the study. There were 38 weeks of Sure-T wear and 39 weeks of Quick-Set wear with no difference in the survival curves of the infusion sets. There was, however, a 15% initial failure rate with the Teflon infusion set. After 7 days, both types of infusion sets had a 64% failure rate. Overall, 30% failed because of hyperglycemia and a failed correction dose, 13% were removed for pain, 10% were pulled out by accident, 10% had erythema and/or induration of>10 mm, 5% fell out because of loss of adhesion, and 4% were removed for infection. The main predictor of length of wear was the individual subject. There was no increase in hyperglycemia or daily insulin requirements when an infusion set was successfully used for 7 days (n=25 of 77 weeks). CONCLUSIONS: We found no difference between steel and Teflon infusion sets in their function over 7 days, although 15% of Teflon sets failed because of kinking on insertion. The strongest predictor of prolonged 7-day infusion set function was the individual subject, not the type of infusion set.
Authors: Jamie R Wood; Elaine C Moreland; Lisa K Volkening; Britta M Svoren; Deborah A Butler; Lori M B Laffel Journal: Diabetes Care Date: 2006-11 Impact factor: 19.112
Authors: R S Mecklenburg; E A Benson; J W Benson; B A Blumenstein; P N Fredlund; T S Guinn; R J Metz; R L Nielsen Journal: N Engl J Med Date: 1985-08-22 Impact factor: 91.245
Authors: R S Mecklenburg; E A Benson; J W Benson; P N Fredlund; T Guinn; R J Metz; R L Nielsen; C A Sanner Journal: JAMA Date: 1984-12-21 Impact factor: 56.272
Authors: Louise S Conwell; Elena Pope; Ana M Artiles; Arun Mohanta; Alan Daneman; Denis Daneman Journal: J Pediatr Date: 2008-01-22 Impact factor: 4.406
Authors: Gregory P Forlenza; Sunil Deshpande; Trang T Ly; Daniel P Howsmon; Faye Cameron; Nihat Baysal; Eric Mauritzen; Tatiana Marcal; Lindsey Towers; B Wayne Bequette; Lauren M Huyett; Jordan E Pinsker; Ravi Gondhalekar; Francis J Doyle; David M Maahs; Bruce A Buckingham; Eyal Dassau Journal: Diabetes Care Date: 2017-06-05 Impact factor: 19.112
Authors: Daniel P Howsmon; Nihat Baysal; Bruce A Buckingham; Gregory P Forlenza; Trang T Ly; David M Maahs; Tatiana Marcal; Lindsey Towers; Eric Mauritzen; Sunil Deshpande; Lauren M Huyett; Jordan E Pinsker; Ravi Gondhalekar; Francis J Doyle; Eyal Dassau; Juergen Hahn; B Wayne Bequette Journal: J Diabetes Sci Technol Date: 2018-02-01